AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Dosage for Humira (adalimumab) may vary based on the condition it’s being used to treat. Also, your doctor may adjust your dosage over the course of your treatment. Be sure to take the Humira ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

As with other drugs, Humira (adalimumab) can cause side effects, such as headache and injection site reactions. If you are not able to tolerate side effects of Humira, talk with your doctor or ...

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US. Alvotech is challenging the patent thicket ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Explore some of the top defensive stocks to buy and hold ahead of Donald Trump's Liberation Day tariffs next week ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...